ADVENTRX Acquires SynthRx
pp体育直播 provides merger and acquisition services within their Chemicals Group.
April 2011ADVENTRX Pharmaceuticals, Inc. () announced the completion its acquisition of SynthRx, Inc. SynthRx’s lead product candidate is a novel, proprietary, rheologic and antithrombotic compound, poloxamer 188, that ADVENTRX will develop as ANX-188.
By adding ANX-188 to their pipeline, ADVENTRX will have another late-stage sickle cell asset with multiple development opportunities.
About ADVENTRX
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing novel, clinical-stage therapies for serious or life-threatening diseases with significant unmet needs. ADVENTRX has built their product pipeline through the strategic acquisition of privately-held companies with clinical-stage assets and we currently are focused on developing new therapies for heart failure, a condition with a high unmet need for innovative treatment options.
About Scott Macon’s Chemical Industries Group and M&A Services
Our chemicals practice professionals serve with more than 30 years of experience, and possess significant chemicals investment banking experience from serving a wide range of clients in the industry. pp体育直播’s Chemical transaction group includes corporate advisory and strategic advisory as well as capital market assignments in both the public and private markets.
In addition to the outright sale of a company or business unit, pp体育直播鈥檚 professionals have experience in a wide range of shareholder and liquidity-driven transactions. pp体育直播 professionals have significant experience assisting clients in acquiring businesses, either as stand-alone acquisitions or for integration into existing client operations. Our clients have ranged from large global corporations looking to expand their existing operations to private equity funds seeking to build a new or existing portfolio investment.